Euronews • 3/23/2026

Pfizer and Valneva's Lyme disease vaccine has demonstrated 70% efficacy in clinical trials. The companies report that these promising results could lead to regulatory approval, despite facing setbacks due to fewer cases than expected.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.













